EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients

Yen-Hao Chen, Yen-Yang Chen, Jing-Houng Wang, Chao-Hung Hung

Anticancer Research · 2023

DOI: 10.21873/anticanres.16286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Yen-Hao Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicin…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansBevacizumabAntibodies, Monoclonal, HumanizedPhenylurea CompoundsQuinolines

Stichwörter der Autor:innen

Atezolizumabbevacizumabhepatocellular carcinomalenvatinib

Substanzen

BevacizumabatezolizumabAntibodies, Monoclonal, HumanizedlenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, R.O.C.; alex8701125@gmail.com.
  • School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan, R.O.C.
  • School of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.
  • Department of Nursing, School of Nursing, Fooyin University, Kaohsiung, Taiwan, R.O.C.
  • Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, R.O.C.
  • Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, R.O.C.

Zitieren

APA

Chen, Y. H., Chen, Y. Y., Wang, J. H., & Hung, C. H. (2023). Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients. Anticancer Research. https://doi.org/10.21873/anticanres.16286

Vancouver

Chen YH, Chen YY, Wang JH, Hung CH. Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients. Anticancer Research. 2023. doi:10.21873/anticanres.16286

BibTeX
@article{Chen2023,
  author = {Chen, Yen-Hao and Chen, Yen-Yang and Wang, Jing-Houng and Hung, Chao-Hung},
  title = {Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16286}
}
Kostenlos starten →